|
|
Shanghai Minwei Biotechnology Co., Ltd. was founded in 2021 and is located in the Zhoupu Town of Zhangjiang Science City, Pudong New Area, Shanghai, a hub for innovative biopharmaceutical and medical device research and development companies. The company specializes in the innovation and platform development of cutting-edge "multi-core large molecule biopharmaceuticals," aiming to create globally competitive novel drugs.
After the laboratory became operational in July 2021, the R&D team fully dedicated themselves to advancing the development of innovative medicines. By September 2022, they had submitted the pre-IND application for their first drug, MWN101, setting a record-breaking pace for the development of innovative biopharmaceuticals!
With the mission of "striving to occupy the commanding heights of global multi-target biopharmaceuticals and participating in global competition," the company possesses three independent and proprietary innovative drug development systems.
The GPCR agonist screening platform, LAGMA, focuses on metabolic diseases and their complications, as well as cardiovascular diseases. Meanwhile, Minwei Biotechnology has developed the RAF ultra-long-acting molecular development platform, which creates recycling antibodies that can significantly reduce the clinical dosage of drugs, extend dosing intervals, and alleviate the financial burden on patients.
At present, Minwei has a number of research and development pipelines, and nearly 20 clinical approvals at home and abroad. One of the projects has completed phase II multi-center clinical trials for two indications, and several projects have carried out phase I clinical trials at the same time.
Minwei Biotechnology is committed to continuous improvement and prioritizes the needs of the people, developing higher-quality drugs and more advanced technology platforms for the public. Your ideas and suggestions are greatly appreciated. Please feel free to contact us.
We are sincerely at your service.
